首页> 外文OA文献 >Cross-reactivity of antipneumococcal surface protein C (PspC) antibodies with different strains and evaluation of inhibition of human complement factor H and secretory IgA binding via PspC
【2h】

Cross-reactivity of antipneumococcal surface protein C (PspC) antibodies with different strains and evaluation of inhibition of human complement factor H and secretory IgA binding via PspC

机译:抗肺炎球菌表面蛋白C(PspC)抗体与不同菌株的交叉反应性以及通过PspC抑制人补体因子H和分泌型IgA结合的评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Pneumococcal surface protein C (PspC) is an important candidate for a cost-effective vaccine with broad coverage against pneumococcal diseases. Previous studies have shown that Streptococcus pneumoniae is able to bind to both human factor H (FH), an inhibitor of complement alternative pathway, and human secretory IgA (sIgA) via PspC. PspC was classified into 11 groups based on variations of the gene. In this work, we used three PspC fragments from different groups (PspC3, PspC5, and PspC8) to immunize mice for the production of antibodies. Immunization with PspC3 induced antibodies that recognized the majority of the clinical isolates as analyzed by Western blotting of whole-cell extracts and flow cytometry of intact bacteria, while anti-PspC5 antibodies showed cross-reactivity with the paralogue pneumococcal surface protein A (PspA), and anti-PspC8 antibodies reacted only with the PspC8-expressing strain. Most of the isolates tested showed strong binding to FH and weaker interaction with sIgA. Preincubation with anti-PspC3 and anti-PspC5 IgG led to some inhibition of binding of FH, and preincubation with anti-PspC3 partially inhibited sIgA binding in Western blotting. The analysis of intact bacteria through flow cytometry showed only a small decrease in FH binding after incubation of strain D39 with anti-PspC3 IgG, and one clinical isolate showed inhibition of sIgA binding by anti-PspC3 IgG. We conclude that although anti-PspC3 antibodies were able to recognize PspC variants from the majority of the strains tested, partial inhibition of FH and sIgA binding through anti-PspC3 antibodies in vitro could be observed for only a restricted number of isolates.
机译:肺炎球菌表面蛋白C(PspC)是一种具有成本效益的疫苗的重要候选人,该疫苗具有广泛的抗肺炎球菌疾病的能力。先前的研究表明,肺炎链球菌能够通过PspC结合人类因子H(FH)(一种补体替代途径的抑制剂)和人类分泌型IgA(sIgA)。根据基因的变异,将PspC分为11组。在这项工作中,我们使用了来自不同组(PspC3,PspC5和PspC8)的三个PspC片段免疫小鼠以产生抗体。 PspC3诱导的抗体的免疫识别了大多数临床分离株,如通过全细胞提取物的Western印迹和完整细菌的流式细胞术分析所分析的,而抗PspC5抗体则与旁系肺炎球菌表面蛋白A(PspA)具有交叉反应性,抗PspC8抗体仅与表达PspC8的菌株反应。测试的大多数分离株显示出与FH的强结合力,与sIgA的相互作用较弱。与抗PspC3和抗PspC5 IgG的预温育导致FH结合的某些抑制,并且与抗PspC3的预温育在蛋白质印迹中部分抑制sIgA的结合。通过流式细胞仪分析完整细菌,显示菌株D39与抗PspC3 IgG孵育后FH结合仅少量下降,并且一种临床分离株显示抗PspC3 IgG抑制sIgA结合。我们得出的结论是,尽管抗PspC3抗体能够从大多数测试菌株中识别PspC变体,但是对于有限数量的分离物,在体外只能通过抗PspC3抗体观察到FH和sIgA结合的部分抑制。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号